Vaccine最新文献

{"title":"Non-specific effects of vaccines: The status and the future","authors":"Christine Stabell Benn","doi":"10.1016/j.vaccine.2025.126884","DOIUrl":"10.1016/j.vaccine.2025.126884","url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126884"},"PeriodicalIF":4.5,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143419307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of HPV vaccine disinformation and misinformation in disadvantaged educational settings in Ireland: A multi-year analysis of a school immunisation system","authors":"Allison Deane ,&nbsp;Christine White ,&nbsp;Yvonne Morrissey ,&nbsp;Lucy Jessop ,&nbsp;Suzanne Cotter ,&nbsp;Lois O. Connor ,&nbsp;Vicky McKenna ,&nbsp;Aishwarya Vivekkumar ,&nbsp;Tony Fitzgerald ,&nbsp;Chantal Migone","doi":"10.1016/j.vaccine.2025.126868","DOIUrl":"10.1016/j.vaccine.2025.126868","url":null,"abstract":"<div><h3>Purpose</h3><div>Introduced in 2010, Ireland's school-based HPV immunisation programme has shown lower vaccine uptake in disadvantaged DEIS (Delivering Equality of Opportunity in Schools) schools compared to non-DEIS schools. This study aims to determine if the HPV vaccine misinformation period (2015–2017) disproportionately affected DEIS schools.</div></div><div><h3>Methods</h3><div>This is a register-based cohort study that used routinely collected data on HPV vaccination uptake in girls only, combined with DEIS status from the Department of Education. The analysis covered six academic years (2013–2019), focusing on three periods: 1) Prior to vaccine misinformation (academic years 2013–2014/2014–2015), 2) During misinformation (academic years 2015–2016/2016–2017), and 3) Recovery (academic years 2017–2018/2018–2019).</div></div><div><h3>Results</h3><div>Overall HPV vaccination uptake was 84.8 % before the misinformation, dropped to 55.2 % during the misinformation, and increased to 72.9 % during the recovery period. The uptake difference between DEIS and non-DEIS schools was 4.5 % (95 % CI 1.80–7.17) before the misinformation, 8.0 % (95 % CI 5.35–10.68) during misinformation, and 12.4 % (95 % CI 9.80–14.91) in the recovery period, with DEIS schools showing reduced recovery compared to non-DEIS schools (64.5 % vs 76.5 %; <em>p</em> &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>HPV vaccine misinformation disproportionately affected HPV vaccine uptake in disadvantaged schools. Tailored interventions are needed to address this disparity in DEIS schools.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126868"},"PeriodicalIF":4.5,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024","authors":"Thomas Monchausse ,&nbsp;Titouan Launay ,&nbsp;Louise Rossignol ,&nbsp;Fatima Ait El Belghiti ,&nbsp;Sylvain Brisse ,&nbsp;Nicole Guiso ,&nbsp;Lore Merdrignac ,&nbsp;Carla Rodrigues ,&nbsp;Isabelle Parent du Châtelet ,&nbsp;Aubane Renard ,&nbsp;Julie Toubiana ,&nbsp;Thomas Hanslik ,&nbsp;Thierry Blanchon ,&nbsp;Olivier Steichen ,&nbsp;Marion Debin","doi":"10.1016/j.vaccine.2025.126862","DOIUrl":"10.1016/j.vaccine.2025.126862","url":null,"abstract":"<div><div>The French national surveillance of pertussis consists of several units, including general practitioners (GPs). Here, we report on the clinical characteristics of cases from January to December 2024 from primary care surveillance in France.</div><div>During this period, a total of 689 pertussis cases were reported by GPs participating in the surveillance. The national incidence rate in general practice was estimated to be 244 cases per 100,000 inhabitants (95 % CI: 224–264). Sixty-one per cent of cases were female and 86 % had received at least one dose of pertussis vaccine. Among cases vaccinated with at least three doses, 77 % had been vaccinated for less than 5 years. The median age of the cases was 13 years, with children aged 1 to 6 years old being the most affected population.</div><div>We reported here an increase in the incidence of pertussis in primary care in France since the beginning of 2024, peaking in July 2024. The characteristics of the cases appear to have shifted towards younger age and a higher proportion of individuals who had received at least one dose of the pertussis vaccine in their lifetime, regardless of whether it was administered according to the recommended schedule, compared with previous outbreaks. This study highlights the need for timely vaccination, especially in the young population.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126862"},"PeriodicalIF":4.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foot-and-mouth disease vaccine quality: A universal test for intact viral capsids based on detection of VP4","authors":"S. Berryman ,&nbsp;A. Asfor ,&nbsp;E. Benham ,&nbsp;N. Howe ,&nbsp;A. Burman ,&nbsp;E. Brocchi ,&nbsp;S. Grazioli ,&nbsp;T.J. Tuthill","doi":"10.1016/j.vaccine.2025.126845","DOIUrl":"10.1016/j.vaccine.2025.126845","url":null,"abstract":"<div><div>Foot-and-mouth disease virus (FMDV) causes an economically devastating disease of livestock that is controlled in endemic areas by vaccines containing intact inactivated FMDV particles. In this study, a novel monoclonal antibody named 5B6 has been identified and characterised, that permits the detection of all serotypes of FMDV <em>via</em> a conserved epitope near the N-terminus of the VP4 capsid protein. The antibody recognises intact virus particles known as 146S (the protective antigen) which contain VP4 and not dissociated capsids known as 12S (poorly protective antigen) which lack VP4. This allowed the development of a universal assay to specifically detect the protective antigen in vaccine samples using a simple ELISA. Such a test could be used to assess the quality of formulated vaccine following manufacture or prior to administration, or to assess unformulated vaccine antigen, and would be of great utility to enhance the effectiveness of FMD vaccination programmes.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126845"},"PeriodicalIF":4.5,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143403449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine (aQIVc) in adults aged 50 years and older","authors":"Brandon J. Essink ,&nbsp;Wim Vermeulen ,&nbsp;Coralie Andrade ,&nbsp;Richard de Rooij ,&nbsp;Leah Isakov ,&nbsp;Daniela Casula ,&nbsp;Frank R. Albano","doi":"10.1016/j.vaccine.2025.126791","DOIUrl":"10.1016/j.vaccine.2025.126791","url":null,"abstract":"<div><div>Influenza poses a significant global healthcare burden, with up to 1 billion infections annually, and poorer outcomes in vulnerable populations such as older adults. Vaccination effectiveness is often lower in elderly individuals. By adding an adjuvant and using cell-based vaccine production methods, the MF59-adjuvanted quadrivalent cell-based influenza vaccine (aQIVc) may boost immunogenicity and vaccine effectiveness in this population. We report the results of a randomised proof-of-concept study, investigating the immunogenicity and safety of aQIVc. Eligible participants aged ≥50 years were randomised 1: 1:1:1 to receive aQIVc (<em>n</em> = 116), a non-adjuvanted quadrivalent cell-based influenza vaccine (QIVc; <em>n</em> = 119), an MF59-adjuvanted quadrivalent egg-based influenza vaccine (aQIV; n = 116), or a high-dose quadrivalent recombinant influenza vaccine (QIVr; <em>n</em> = 120). The primary objective was to assess immunogenicity of aQIVc vs the comparators by haemagglutination inhibition (HI) assay 28 days post-vaccination. Secondary objectives included immunogenicity of aQIVc vs comparators 28 days and 180 post-vaccination by microneutralisation assay and 180 days post-vaccination by HI assay; and reactogenicity and safety of all study vaccines. Compared with QIVc and aQIV, aQIVc elicited a higher immune response (adjusted geometric mean titre [GMT] ratio range 1.18–1.85) against all four influenza strains at Day 29. Against QIVr, aQIVc elicited lower responses against A strains (adjusted GMT ratio range 0.79–0.84), and higher responses against B strains (adjusted GMT ratio range 1.15–1.26). Estimated GMT ratios were generally higher in the subgroup of participants aged ≥65 years vs those aged 50–64 years. aQIVc was well tolerated, eliciting similar rates of solicited local adverse events (AE) and slightly higher rates of solicited systemic AE than aQIV, and a higher rate of all solicited AE than QIVc and QIVr. No safety concern was identified. These data support further investigation of additional formulations of aQIVc in adults aged ≥50 years.</div><div><strong>Clinical trial registry:</strong> <span><span>NCT04576702</span><svg><path></path></svg></span></div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126791"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shielding the immunocompromised: COVID-19 prevention strategies for patients with primary and secondary immunodeficiencies","authors":"Giulio Olivieri ,&nbsp;Donato Amodio ,&nbsp;Emma Concetta Manno ,&nbsp;Veronica Santilli ,&nbsp;Nicola Cotugno ,&nbsp;Paolo Palma","doi":"10.1016/j.vaccine.2025.126853","DOIUrl":"10.1016/j.vaccine.2025.126853","url":null,"abstract":"<div><div>The COVID-19 pandemic has significantly impacted immunocompromised patients, particularly those with inborn errors of immunity (IEI), transplant recipients, hematologic malignancies, and those undergoing treatment with immunosuppressive biologics and medications. These patients face an elevated risk of experiencing severe or even fatal consequences following SARS-CoV-2 infections. Vaccination is the primary defense against COVID-19; however, immune responses following immunization are often suboptimal in these patients, with variable specific humoral response rates. Despite the expedited regulatory approval and the widespread implementation of COVID-19 vaccines, the efficacy and safety for immunocompromised populations require thorough investigation. In future pandemics, including vulnerable populations (VPs) in vaccine and monoclonal antibody (mAb) trials is crucial to develop safe, effective immunization strategies, address gaps in vaccine efficacy and safety data, and create tailored guidelines for at-risk groups. This review provides a comprehensive examination of the efficacy of COVID-19 vaccines and mAbs in patients with primary and secondary immunodeficiency, with a specific focus on individuals with IEI, considering previous regulatory aspects and the necessity of including VPs in vaccine trials to enhance the quality of patient care and promote equitable health outcomes in future pandemics.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"51 ","pages":"Article 126853"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143395781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in mice","authors":"Matthew E. Sherman ,&nbsp;Jane Michalski ,&nbsp;Sayan Das ,&nbsp;Hyojik Yang ,&nbsp;Lakshmi Chandrasekaran ,&nbsp;Timothy R. O'Meara ,&nbsp;David J. Dowling ,&nbsp;Ofer Levy ,&nbsp;Shoshana Barnoy ,&nbsp;Malabi Venkatesan ,&nbsp;Robert K. Ernst","doi":"10.1016/j.vaccine.2025.126779","DOIUrl":"10.1016/j.vaccine.2025.126779","url":null,"abstract":"<div><div><em>Shigella spp.</em> infection contributes significantly to the global disease burden, primarily affecting young children in developing countries. Currently, there are no FDA-approved vaccines against <em>Shigella,</em> and the prevalence of antibiotic resistance is increasing, making therapeutic options limited. Live-attenuated vaccine strains WRSs2 (<em>S. sonnei</em>) and WRSf2G12 (<em>S. flexneri</em> 2a) are highly immunogenic, making them promising vaccine candidates, but possess an inflammatory lipid A structure on their lipopolysaccharide (LPS; also known as endotoxin). Here, we utilized bacterial enzymatic combinatorial chemistry (BECC) to ectopically express lipid A modifying enzymes in WRSs2 and WRSf2G12, as well as their respective wild-type strains, generating targeted lipid A modifications across the <em>Shigella</em> backgrounds. Dephosphorylation of lipid A, rather than deacylation, reduced LPS-induced TLR4 signaling <em>in vitro</em> and dampened endotoxic effects <em>in vivo</em>. These BECC-modified vaccine strains retained the phenotypic traits of their parental strains, such as invasion of epithelial cells and immunogenicity in mice without adverse endotoxicity. Overall, our observations suggest that BECC-engineered live attenuated vaccines are a promising approach to safe and effective <em>Shigella</em> vaccines.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"50 ","pages":"Article 126779"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modelling the impact and cost effectiveness of universal varicella vaccination in England.","authors":"L. Adams ,&nbsp;A. Karachaliou Prasinou ,&nbsp;C. Trotter","doi":"10.1016/j.vaccine.2025.126831","DOIUrl":"10.1016/j.vaccine.2025.126831","url":null,"abstract":"<div><h3>Introduction</h3><div>Two distinct diseases are attributable to the varicella zoster virus, varicella (chickenpox) and zoster (shingles). This study assesses the impact and cost-effectiveness of a childhood varicella vaccination program in England.</div></div><div><h3>Methods</h3><div>We use an age-structured dynamic transmission model and a health economic decision tree. The model incorporates recent data on varicella and zoster epidemiology, including the effects of exogenous boosting on zoster incidence. By simulating various vaccination strategies, including routine and catch-up programs, the study evaluates the potential reduction in varicella and zoster cases due to vaccination and the associated vaccine cost-effectiveness (from the NHS perspective).</div></div><div><h3>Results</h3><div>We find that a two-dose varicella vaccination program could significantly reduce varicella incidence, potentially achieving near-elimination if high coverage rates are maintained. However, the model also predicts a temporary increase in zoster incidence due to reduced natural boosting from varicella exposure; this is partly mitigated by the current zoster vaccination program and the effect is much less substantial than previously estimated. Cost-effectiveness analyses reveal that all vaccination strategies modelled are cost-effective at typical thresholds, with the routine vaccination scenario being the most economically advantageous. Sensitivity analyses demonstrate that vaccine price and varicella treatment costs are the primary drivers of cost-effectiveness.</div></div><div><h3>Conclusion</h3><div>The study supports the introduction of a childhood varicella vaccination program in England, which offers substantial health benefits and is highly likely to be cost-effective.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"50 ","pages":"Article 126831"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143387931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups – The CONVERS project, report from a pediatric tertiary hospital","authors":"Nicola Cotugno ,&nbsp;Marco Sanna ,&nbsp;Donato Amodio ,&nbsp;Elena Morrocchi ,&nbsp;Chiara Pighi ,&nbsp;Chiara Medri ,&nbsp;Giuseppe Rubens Pascucci ,&nbsp;Veronica Santilli ,&nbsp;Emma Concetta Manno ,&nbsp;Paola Zangari ,&nbsp;Chiara Rossetti ,&nbsp;Nicole Colantoni ,&nbsp;Giulio Olivieri ,&nbsp;Elena Emili ,&nbsp;Alessia Neri ,&nbsp;Arianna Rotili ,&nbsp;Paolo Rossi ,&nbsp;Ofer Levy ,&nbsp;Lorenza Putignani ,&nbsp;Paolo Palma ,&nbsp;Gioacchino Andrea Rotulo","doi":"10.1016/j.vaccine.2025.126778","DOIUrl":"10.1016/j.vaccine.2025.126778","url":null,"abstract":"<div><h3>Background</h3><div>Whereas several studies have demonstrated the long-term immunogenicity of BNT162b2 vaccine in healthy adults, little evidence was provided in vulnerable populations (VPs) with generally low ability to respond to immunizations. We aimed to identify pre-vaccination immune phenotype and transcriptional signatures in B and T-cell subsets associated with immune response and long-term maintenance upon SARS-CoV-2 vaccination in VPs.</div></div><div><h3>Methods</h3><div>A cohort of VPs (<em>N</em> = 169) including solid organ transplant recipients (SOT; <em>N</em> = 35), Inflammatory Bowel Disease (<em>N</em> = 31), Down Syndrome (<em>N</em> = 42), people living with HIV (<em>N</em> = 36), primary immune deficiencies (<em>N</em> = 25) and healthy controls (<em>N</em> = 37) were enrolled in the CONVERS Study. SARS-CoV-2 Vaccine responsiveness was evaluated by SARS-CoV-2–specific Ab and SARS-CoV-2–specific CD4+ T cells in VPs naive to infection or vaccination. Based on the humoral response at T28, individuals were classified as Protected (P: anti-spike antibody [anti-S] titer ≥0.8) and Not-Protected (NP: anti-S titer &lt;0.8). Peripheral blood mononuclear cells, after SARS-CoV-2 Prot-S peptides stimulation were sort-purified in four cell subsets and analyzed by multiplexed RT-PCR (Fluidigm, Biomark).</div></div><div><h3>Results</h3><div>SOT presented a significantly lower serological immunogenicity with 31 % of individuals being NP at T28 whereas only 1 out of the remaining 119 resulted Ab negative at T28. At T0, NP individuals showed a lower increase of Ag specific CD40L+ T cells and lower switched memory B cells compared to P patients. Gene-expression analysis revealed distinct signatures at baseline between P and NP individuals with 63 and 49 DEGs identified in two experimental conditions, respectively unstimulated and stimulated.</div></div><div><h3>Conclusions</h3><div>Pre-vaccination B and T-cell characteristics at both phenotypic and gene- expression level correlate with short- and long- term memory maintenance in VPs with lower immunogenicity upon BNT162b2 vaccine. Such signatures need to be validated in larger cohorts and may provide a predictive score to inform personalized and more effective vaccine interventions.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"49 ","pages":"Article 126778"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of caregiver vaccination status on child influenza vaccination hesitancy: A time-to-vaccination analysis for 2023–2024 season in the Republic of Korea","authors":"So-Yeon Kim ,&nbsp;Minju Song ,&nbsp;Seunghyun Lewis Kwon","doi":"10.1016/j.vaccine.2025.126852","DOIUrl":"10.1016/j.vaccine.2025.126852","url":null,"abstract":"<div><div>Children face heightened risks of severe influenza compared to healthy adults. Republic of Korea provides free influenza vaccinations to children aged 6 months to 13 years. Global vaccine hesitancy has surged amidst the COVID-19 pandemic. This study assesses how caregivers' vaccination status influences childhood influenza vaccination hesitancy using national data from the 2023–2024 period. Analyzing data from the Korea Disease Control and Prevention Agency's Immunization Registry Information System, focusing on 2-year-old children, 93.0 % were eligible after excluding those who didn't complete the initial two-dose schedule. ‘Time to Vaccination’ spanned from the program's inception to inoculation. Cox proportional hazards regression found children were 1.53 times more likely to get vaccinated if their caregiver had been, with significance (Exp(B) = 1.531, <em>p</em> &lt; .001). Female gender and text message reminders were also influential. These results underscore caregiver vaccination's pivotal role in curbing childhood influenza vaccination hesitancy.</div></div>","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"49 ","pages":"Article 126852"},"PeriodicalIF":4.5,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143386909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}